Incyte reports 24-week data for Opzelura cream in moderate atopic dermatitis

May 7, 2026 8:50 AM

Incyte (NASDAQ: INCY) announced 24-week results from its Phase 3 TRuE-AD4 study of Opzelura cream for adults with moderate atopic ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found